Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers

NCT02829372 is registered in ClinicalTrials.gov with Ichnos Sciences SA as lead sponsor.

NCT NCT02829372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02829372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers
Lead sponsor
Ichnos Sciences SA
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2016
Completion date
May 31, 2019
Enrollment
36 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

her2 expressing solid tumours